Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Virtus Artificial Intelligence & Technology Opportunities Fund Discloses Sources of Distribution – Section 19(a) Notice
-
Hess Midstream LP Announces Secondary Public Offering of Class A Shares
-
U.S. Physical Therapy Announces Dual Listing on NYSE Texas
-
CSB Bancorp, Inc. Declares Second Quarter Cash Dividend
-
LifeStance to Present at the 46th Annual Goldman Sachs Healthcare Conference
-
Sanuwave Health Selected for Inclusion in Russell 2000® Index
-
AI-Powered Quality Inspection Poised to Unlock Billions in Global Corporate Savings
-
Global Medical REIT Inc. Board Declares 2025 Second Quarter Common and Preferred Dividends
-
CoreMap, Inc. Receives U.S. FDA Investigational Device Exemption (IDE) Approval for INvENI Map-Guided AF Ablation Study
-
OGN INVESTOR NOTICE: Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
IPM Provides Secure, Scalable, and Expertly Managed IT Services to More Effectively Onboard the Private Equity Clients of IT Ally
-
FP Newspapers Inc. Results of Annual Meeting of Shareholders
-
Oxford to Release First Quarter Fiscal 2025 Results on June 11, 2025
-
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
-
Signal Technologies Appoints Ryan Story as SVP of Operations Amid Rapid Growth in Canada to US Vehicle Export Market
-
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
-
MillerKnoll Schedules Fourth Quarter and Full Fiscal Year 2025 Conference Call and Webcast
-
Synopsys Posts Financial Results for Second Quarter Fiscal Year 2025
-
SEI Declares Dividend of $0.49 per Share
-
Nanalysis Announces First Quarter 2025 Results
-
Halozyme to Participate at Upcoming Investor Conferences
-
Katahdin Bankshares Corp. Announces Quarterly Dividend
-
e.l.f. Beauty Announces Fourth Quarter and Full Fiscal 2025 Results
-
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
-
Agilent Reports Second-Quarter Fiscal Year 2025 Financial Results
-
ICF to Present at the Baird 2025 Global Consumer, Technology & Services Conference
-
Veeva Announces Fiscal 2026 First Quarter Results
-
Smith Douglas Homes Corp. Announces Stock Repurchase Program
-
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update
-
SentinelOne Announces First Quarter Fiscal Year 2026 Financial Results
-
Jack in the Box Inc. Announces Dawn Hooper as Its Chief Financial Officer
-
Virtus Diversified Income & Convertible Fund Discloses Sources of Distribution – Section 19(a) Notice
-
Domo Named to the 2025 ParityLIST, a Parity.Org Program Recognizing the Best Companies for Equal Advancement Opportunity
-
Xponential Fitness, Inc. to Host Analyst and Investor Day Tomorrow
-
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference
-
Viking Therapeutics to Participate at Upcoming Investor Conferences
-
JetBlue to Participate in TD Cowen’s Future of the Consumer Conference
-
e.l.f. Beauty Announces Definitive Agreement to Acquire rhode in $1 Billion Deal
-
Pool Corporation Announces Upcoming Investor Conference Participation
-
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
-
C3 AI and Baker Hughes Renew and Expand Joint Venture Agreement
-
Ulta Beauty to Participate in Upcoming Investor Conference
-
MiningNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Reaches Key Milestone at Montauban as Canadian Gold Sector Gains Strength
-
Sana Biotechnology to Present at June 2025 Investor Conferences
-
Outdoor Holding Company Announces Settlement and Leadership Transition
-
XCEL BRANDS, INC. Receives NASDAQ notice regarding delinquent Form 10-K and Form 10-Q filing
-
nCino Reports First Quarter Fiscal Year 2026 Financial Results
-
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients
-
Brilliant Earth Announces Participation in the TD Cowen 9th Annual Future of the Consumer Conference and Noble Capital Markets Emerging Growth Virtual Equity Conference
-
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

